Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$73.95
-2.38 (-3.12%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-108.1M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-17.8%
↓Gross Margin
8.2%
↓Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-27.3%
FCF CAGR
—
FCF margin
-95.8%
FCF / Net income
1.45x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $154.2M · net income $-102.2M · FCF $-147.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $154.2M | $154.2M | $240.6M | $334.3M | $401.0M |
| Net Income | $-102.2M | $-102.2M | $-62.7M | $18.9M | $20.5M |
| EBITDA | $-61.1M | $-61.1M | $-48.4M | $44.3M | $38.2M |
| EPS | -1.29 | -1.29 | -0.79 | 0.24 | 0.26 |
| Gross Margin | 8.2% | 8.2% | 42.4% | 68.6% | 77.0% |
| Operating Margin | -61.3% | -61.3% | -29.4% | 3.6% | 4.1% |
| Net Margin | -66.3% | -66.3% | -26.0% | 5.6% | 5.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.49 | 0.23 | 0.13 |
| Current Ratio | 0.73 | 0.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-147.6M | $-147.6M | $-108.1M | $-11.3M | $-31.6M |
| Returns | |||||
| ROE | -17.8% | -17.8% | -9.3% | 2.4% | 2.7% |
| Valuation | |||||
| P/E | — | — | — | 111.17 | 124.92 |
| EV/EBITDA | — | — | — | 42.25 | 58.63 |
| P/B | 10.19 | 10.19 | 2.00 | 2.71 | 3.41 |
| Growth & Yield | |||||
| Revenue Growth | -35.9% | -35.9% | -28.0% | -16.6% | — |
| EPS Growth | -63.3% | -63.3% | -429.2% | -7.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+199.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.79 → -1.29
Residual
+199.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.